<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="3575">
  <stage>Registered</stage>
  <submitdate>14/06/2012</submitdate>
  <approvaldate>14/06/2012</approvaldate>
  <nctid>NCT01624246</nctid>
  <trial_identification>
    <studytitle>Pharmacokinetic Study of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance</studytitle>
    <scientifictitle>A Phase 1, Multicenter, Open-label, Single-dose Study to Assess the Pharmacokinetics of Ceftaroline Fosamil/Avibactam in Adults With Augmented Renal Clearance</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>CXL-PK-04</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Augmented Renal Clearance (ARC)</healthcondition>
    <healthcondition>Systemic Inflammatory Response Syndrome (SIRS)</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Ceftaroline fosamil/Avibactam (CXL)

Experimental: Ceftaroline fosamil/Avibactam - 


Treatment: drugs: Ceftaroline fosamil/Avibactam (CXL)
IV infusion of CXL (combination of ceftaroline fosamil [600 mg] plus avibactam [600 mg]) infused over 60 (± 5) minutes.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Plasma Pharmacokinetic Parameters of Ceftaroline and Avibactam: Area under the plasma concentration versus time curve, Cmax, Tmax, T½, , CL, Vz, and Vss. - The following PK parameters, if calculable, will be determined for ceftaroline, ceftaroline fosamil, ceftaroline M-1, and avibactam: area under the plasma concentration versus time curve, Cmax, time of maximum plasma drug concentration (Tmax), T½, apparent total body clearance of drug from plasma (CL), apparent volume of distribution during the terminal phase (Vz), and Vss.</outcome>
      <timepoint>Up to 3 days</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Safety and Tolerability of a Single Dose of IV Ceftaroline fosamil and Avibactam. - Adverse events will be summarized. Vital signs (pulse, blood pressure, respiratory rate, temperature), oxygen saturation and concomitant medications will be summarized. Complete blood count (CBC) and comprehensive metabolic panel results will be summarized.</outcome>
      <timepoint>24-36 hours after last study procedure</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female adults = 18 and = 55 years old

          -  Augmented renal clearance, defined as:

               -  Estimated CrCl = 115 mL/min (calculated using modified Cockcroft-Gault, before
                  the measured 8-hour urine collection)

               -  Measured CrCl = 140 mL/min (from an 8-hour urine collection)

          -  Hospitalized and diagnosed with SIRS, defined by at least 2 of the following:

               -  Temperature (oral, rectal, tympanic, or core) &gt; 38.5°C or &lt; 35.0°C

               -  Heart rate &gt; 90 beats/min

               -  Respiratory rate &gt; 20 breaths/min or PaCO2 &lt; 32 mmHg

               -  Leukocytosis (&gt; 12,000 white blood cells [WBC]/mm3), leukopenia (&lt; 4000 WBC/mm3),
                  or bandemia (&gt; 10% immature neutrophils [bands] regardless of total peripheral
                  WBC)

          -  Requires indwelling urinary bladder catheter per standard of care (through the end of
             the 8-hour urine collection)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>55</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  History of any known hypersensitivity or allergic reaction to cephalosporins or any
             ß-lactam antimicrobial (eg, penicillins)

          -  History of chronic kidney disease, hemodialysis, or peritoneal dialysis; or history of
             acute renal replacement therapy (eg, hemodialysis, hemofiltration) associated with
             current illness

          -  Suspected rhabdomyolysis or creatine kinase &gt; 10,000 U/L

          -  Significant anemia defined as hemoglobin &lt; 9 g/dL or hematocrit &lt; 27%

          -  Transfusion of packed red blood cells (PRBC) or whole blood within 24 hours of study
             drug infusion or anticipated need for a transfusion before the last PK blood sample is
             collected

          -  If female, currently pregnant or breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Single group</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/05/2012</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>12</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2013</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Investigational Site - Herston</hospital>
    <hospital>Investigational Site - Southport</hospital>
    <postcode>4029 - Herston</postcode>
    <postcode>4215 - Southport</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>District of Columbia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Forest Laboratories</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>To evaluate the pharmacokinetic (PK) profiles of ceftaroline and avibactam in adults with
      augmented renal clearance (ARC).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT01624246</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Medical Monitor</name>
      <address>Forest Laboratories</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>